Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Back to Jobs

Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patients Public offering completed for total gross proceeds of $69.1 million Results from Phase 3 trial of OTIVIDEX ® in Ménière’s disease expected in first quarter of 2021 Results from Phase 1/2 trial of OTO-413 in

Apply Now